# Egetis Therapeutics

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/egetistherapeutics).

## Overview

Egetis Therapeutics is an innovative pharmaceutical company specializing in the development and commercialization of treatments for serious diseases with significant unmet medical needs, particularly in the orphan drug segment. The company's lead drug candidate, Emcitate® (tiratricol), is developed for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a rare and debilitating condition. Egetis is also exploring the potential of Emcitate for resistance to thyroid hormone beta (RTHβ), another rare disorder. The company operates primarily in late-stage drug development, aiming to bring novel therapies to market for conditions with no existing treatments.

## Products & services

• Emcitate® (tiratricol) for MCT8 deficiency
• Development of Emcitate for RTHβ
• Managed Access Program for Emcitate
• Orphan Drug Designation applications
• Clinical trials and studies for rare diseases

- **Orphan Drugs** (80%) — Includes drugs for rare diseases with significant unmet needs.
- **Clinical Trials** (15%) — Conducting trials for drug efficacy and safety.
- **Regulatory Approvals** (5%) — Securing approvals for drug commercialization.

- Emcitate® (tiratricol) for MCT8 deficiency
- Development of Emcitate for RTHβ
- Managed Access Program for Emcitate
- Orphan Drug Designation applications
- Clinical trials and studies for rare diseases

## Customers

Egetis Therapeutics primarily serves healthcare providers and patients affected by rare diseases, particularly those with MCT8 deficiency and RTHβ. The company's focus on orphan drugs means its customer base includes hospitals and clinics involved in specialized care for rare conditions. Physicians and healthcare institutions participate in clinical trials and managed access programs to provide patients with early access to new treatments. The company collaborates with academic research groups for investigator-initiated studies, expanding its reach within the medical and scientific communities.

- **Healthcare Providers** (primary) — Purchase Emcitate for treating rare diseases.
- **Academic Research Groups** (secondary) — Collaborate on studies for new indications.
- **Patients and Families** (emerging) — Seek treatments for rare and debilitating conditions.

- Healthcare providers treating rare diseases
- Patients with MCT8 deficiency and RTHβ
- Hospitals participating in clinical trials
- Physicians involved in managed access programs
- Academic research groups for collaborative studies

## Geography

Egetis Therapeutics is based in Sweden and operates primarily within the European Union, where it recently received approval for Emcitate as a treatment for MCT8 deficiency. The company plans to launch Emcitate in Germany, marking its first commercial entry into the EU market. Egetis also engages in clinical trials and regulatory activities in the United States, aiming to expand its geographic footprint. The company's focus on rare diseases necessitates a global approach to reach patients and healthcare providers worldwide.

- Headquartered in Sweden
- EU approval for Emcitate for MCT8 deficiency
- Planned launch in Germany in 2025
- Clinical trials conducted in the US
- Global reach for orphan drug markets

## Strategy

Egetis Therapeutics focuses on advancing its lead candidate, Emcitate, through regulatory approvals and market launches, starting with the EU. The company prioritizes expanding the indications for Emcitate, including RTHβ, to maximize its therapeutic potential. Egetis aims to strengthen its presence in the orphan drug market by securing additional Orphan Drug Designations and leveraging its Managed Access Program. Strategic partnerships with academic institutions and healthcare providers are key to supporting clinical trials and expanding market access.

- **Regulatory Approvals** (short-term) — To commercialize Emcitate in the EU and US.
- **Indication Expansion** (medium-term) — To increase Emcitate's market potential.
- **Market Launch** (medium-term) — To establish a presence in key markets.

- Advance Emcitate through regulatory approvals
- Expand Emcitate indications to RTHβ
- Strengthen orphan drug market presence
- Leverage Managed Access Program for market entry
- Form strategic partnerships for clinical trials

## Risks

Egetis Therapeutics faces several risks, including the inherent uncertainties of pharmaceutical development and regulatory approval processes. The company is exposed to operational risks related to manufacturing, commercialization, and market acceptance of its products. Geopolitical tensions and economic instability could impact its ability to conduct research and development as planned. Additionally, competition from other pharmaceutical companies and potential changes in healthcare regulations pose significant challenges. The company's reliance on successful clinical trial outcomes for Emcitate adds another layer of risk.

- **Regulatory Approval Delays** [critical] — Could delay market entry and revenue generation.
- **Clinical Trial Outcomes** [critical] — Negative results could halt development.
- **Geopolitical Instability** [high] — May disrupt R&D activities.

- Uncertainties in pharmaceutical development
- Regulatory approval challenges
- Operational risks in manufacturing and commercialization
- Geopolitical and economic instability
- Competition from other pharmaceutical companies
- Changes in healthcare regulations
- Dependence on clinical trial outcomes

## Accounting

Egetis Therapeutics applies IFRS as adopted by the EU, with financial statements prepared in SEK. Critical accounting matters include revenue recognition from its Managed Access Program and the impact of clinical trial costs on financial results. The transition from a cost-based to a function-based income statement aligns with industry practices and internal management review processes. Estimates and judgments in financial reporting are significant due to the nature of pharmaceutical development and regulatory activities. The company's financial statements are subject to currency fluctuations, given its international operations.

- **Revenue Recognition**
- **Income Statement Transition**

- IFRS applied for financial reporting
- Revenue recognition from Managed Access Program
- Transition to function-based income statement
- Significant estimates and judgments in reporting
- Currency fluctuations impact financial results

---

*Last updated: 2026-08-11T04:04:51.897342+00:00*